Thermo Fisher Scientific and Zhongen Shengyi Medical are collaborating to advance late-stage clinical production of mesenchymal stem cell therapy.

Terumo BCT and Zhongen Shengyi Medical have reached a strategic partnership agreement, and both parties will work together to optimize and scale up the production process of mesenchymal stem cell therapy in the later clinical stages, with a focus on automated cell expansion technology. Currently, the number of approved therapies in this field globally is limited, and the overall clinical application and commercialization process is relatively slow. One of the bottlenecks is transitioning from the manual production mode that the industry has long relied on to an automated, scalable manufacturing system. Terumo BCT stated to Interface News that the two parties have officially signed an agreement to jointly utilize the Quantum Flex automated cell expansion platform to transfer and optimize Zhongen Shengyi Medical's existing manual processes; if key milestones are achieved in the future, such as meeting the quality and quantity requirements of cells produced by Quantum Flex, this platform will be designated as the production equipment for the later clinical and commercialization stages.